![](/img/cover-not-exists.png)
Potential factors correlating to the PMDA’s decision to waive Japanese Phase 2 and 3 studies for oncology drugs New Drug Application in Japan
Keitaro Nakajima, Koji Chiba, Hisao Tsubamoto, Jaimie Walsh, Laurie Strawn, Toshio SuwaVolume:
31
Language:
english
DOI:
10.1007/s10637-012-9911-x
Date:
August, 2013
File:
PDF, 157 KB
english, 2013